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Abstract
Background: Disorganized angiogenesis is associated with several pathologies, including cancer. The identification
of new genes that control tumor neovascularization can provide novel insights for future anti-cancer therapies.
Sprouty1 (SPRY1), an inhibitor of the MAPK pathway, might be one of these new genes. We identified SPRY1 by
comparing the transcriptomes of untreated endothelial cells with those of endothelial cells treated by the
angiostatic agent 16 K prolactin (16 K hPRL). In the present study, we aimed to explore the potential function of
SPRY1 in angiogenesis.
Results: We confirmed 16 K hPRL induced up-regulation of SPRY1 in primary endothelial cells. In addition, we
demonstrated the positive SPRY1 regulation in a chimeric mouse model of human colon carcinoma in which 16 K
hPRL treatment was shown to delay tumor growth. Expression profiling by qRT-PCR with species-specific primers
revealed that induction of SPRY1 expression by 16 K hPRL occurs only in the (murine) endothelial compartment
and not in the (human) tumor compartment. The regulation of SPRY1 expression was NF-B dependent. Partial
SPRY1 knockdown by RNA interference protected endothelial cells from apoptosis as well as increased endothelial
cell proliferation, migration, capillary network formation, and adhesion to extracellular matrix proteins. SPRY1
knockdown was also shown to affect the expression of cyclinD1 and p21 both involved in cell-cycle regulation.
These findings are discussed in relation to the role of SPRY1 as an inhibitor of ERK/MAPK signaling and to a
possible explanation of its effect on cell proliferation.
Conclusions: Taken together, these results suggest that SPRY1 is an endogenous angiogenesis inhibitor.
Background
Many growth factors including vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor
(bFGF), in association with their receptor tyrosine kinase
(RTK) receptors, play a crucial role in angiogenesis in
normal and pathological settings [1]. Essential to most
RTK-mediated signaling is the activation of the extracel-
lular-signal-regulated kinase/mitogen-activated protein
kinase (ERK/MAPK) signaling cascade. This cascade is
precisely controlled by the activity of various regulatory
proteins [2], including members of the Sprouty (SPRY)
protein family.
SPRY was originally described as an antagonist of
Breathless FGF receptor signaling during tracheal
branching in Drosophila [3]. Four mammalian homologs
(SPRY1-4) have been described and are widely expressed
in embryonic and adult tissues, except for SPRY3 whose
expression is believed to be restricted to the brain and
testes in adults [4]. All SPRY proteins share a highly
conserved, cysteine-rich C-terminal domain and a more
variable N-terminal domain. They are subject to tight
control at multiple levels: differential localization, post-
translational modification, and regulation of protein
levels. SPRY specifically inhibits RTK-mediated Ras-Erk/
MAPK signaling. At which stage SPRY blocks ERK/
MAPK activation remains controversial, and evidence to
date suggests the existence of multiple mechanisms that
depend on the cell context and/or the identity of the
RTK [5-7]. Due to their inhibitory activity on the ERK/
MAPK pathway, SPRY generally acts as a tumor sup-
pressor. Recently, the anti-tumor potential of SPRY4
was shown to be associated with its ability to inhibit
angiogenesis [8]. Moreover, the angiostatic activity of
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both SPRY2 and SPRY4 has also been demonstrated
in vivo in a mouse model of ischemia [9].
Our laboratory and others have identified 16 K prolac-
tin (16 K hPRL), the 16-kDa N-terminal fragment of
human prolactin, and its derived peptides as very potent
angiostatic compounds both in vitro and in vivo [10,11].
16 K hPRL is able to inhibit tumor growth and metastasis
in various mouse models by inhibiting neovascularization
[12-15]. The potential therapeutic use of 16 K hPRL has
also been observed in non-cancer pathological models
like retinopathy [16]. Postpartum cardiomyopathy, a dis-
ease characterized by acute heart failure in women in the
late stage of pregnancy up to several months postpartum,
has been shown to be a consequence of an excessive pro-
duction of 16 K hPRL [17]. To date, the mechanisms by
which 16 K hPRL inhibits angiogenesis have only been
partially elucidated. In bovine endothelial cells, the angio-
static activity of 16 K hPRL appears to be mediated by a
saturable high-affinity binding site distinct from the PRL
receptor [18]. 16 K hPRL triggers endothelial cell apopto-
sis by activation of nuclear factor B (NF-B) [19,20]. In
addition, 16 K hPRL induces endothelial cell cycle arrest
in G0-G1 and G2-M [21], in parallel with inhibition of
bFGF and VEGF stimulated MAPK activation [22]. More
recently, we identified an important link between 16 K
hPRL and the immune system using a transcriptomic
analysis performed on 16 K hPRL-treated endothelial
cells. 16 K hPRL induces leukocyte adhesion to endothe-
lial cells by activating NF-B [23].
Interestingly, SPRY1 was amongst the targets of 16 K
hPRL found in the aforementioned transcriptomic study.
SPRY1 has been implicated in the inhibition of bFGF and
VEGF-induced proliferation and differentiation in vitro
[24], however the physiological role of SPRY1 in angio-
genesis still remains to be elucidated. Here, after con-
firming upregulation of SPRY1 expression by 16 K hPRL
both in vitro (in primary endothelial cells) and in vivo (in
a mouse xenograft tumor model), we performed SPRY1-
knockdown experiments to test the possible involvement
of SPRY1 in regulating angiogenesis. Indeed, SPRY1
emerges as a novel endogenous angiogenesis inhibitor
with potential applicability in the clinic.
Results
16 K hPRL treatment increases SPRY1 mRNA and protein
levels in primary and human endothelial cells
A previously performed differential transcriptomic
study on ABAE (Adult Bovine Aortic Endothelial) cells
cultured with or without the angiostatic compound
16 K hPRL, revealed 216 genes which were differen-
tially expressed [23]. From these 216 genes, we
selected 2-fold up-regulated SPRY1 as a potential new
angiogenesis regulator, notably because of its function
in cell proliferation.
We first confirmed the results of the transcriptomic
analysis by performing a time response analysis of SPRY1
mRNA expression in ABAE. 16 K hPRL treatment
(10 nM) of ABAE cells induced the expression of SPRY1
in ABAE over time, with a maximum up-regulation 4 h
post-treatment. SPRY1 expression returned to base levels
after 6 h of 16 K hPRL treatment (Fig 1A). This regula-
tion was confirmed at the protein level since SPRY1 pro-
tein levels increase gradually after treatment with 16 K
hPRL, reaching a maximum after 4 h (Fig 1B).
SPRY1 expression was also analyzed in a human
endothelial cell line. In HMVECs (human microvascular
endothelial cells), the SPRY1 mRNA level was unde-
tected under basal conditions. However, low levels of
SPRY1 mRNA appeared after 16 K hPRL treatment
(data not shown). Unfortunately, the fold induction was
thus not possible to determine in this case and the
expression level of SPRY1 in HMVECs was too low to
be detected by Western blotting.
To determine whether 16 K hPRL modulates the sub-
cellular localization of SPRY1 in endothelial cells, we
performed an immunofluorescent staining on ABAE
cells. In untreated cells, SPRY1 was distributed through-
out the cells; especially in the perinuclear regions. This
was not changed after 16 K hPRL treatment (Fig 1C)
indicating that 16 K hPRL does not seem to affect
SPRY1 localization.
16 K hPRL increases endothelial SPRY1 expression in vivo
in a mouse xenograft tumor model
We further assessed the regulation of endothelial SPRY1
expression by 16 K hPRL in vivo in a mouse xenograft
tumor model consisting of nude mice injected s.c. with
human HCT116 cells. When tumors reached an average
volume of 150 mm3, mice were treated with 16 K-Ad or
Null-Ad by intra-tumoral injections. In order to verify
that 16 K hPRL was synthesized in the tumors treated
with this vector, Western blot analyses were performed
on protein extracts obtained from 16 K-Ad- and Null-
Ad-treated tumors (Fig 2A). Indeed, the 16 K-Ad-trea-
ted tumors showed high levels of two 16 K hPRL
isoforms, while the two bands were absent in the Null-
Ad treated tumors. As previously reported 16 K hPRL
has the ability to undergo glycosylation and thus appears
in multiple isoforms [16]. We detected a significantly
delay in established HCT116 tumor growth after 16 K-
Ad treatment compared to Null-Ad as depicted by the
tumor growth curves (Fig 2B). This is for the first time
that 16 K hPRL has been shown to reduce established
growth of human tumor cells in vivo.
As the developing human tumors recruit mouse
endothelial cells to form their vasculature in this
model [25], it is possible to measure separately the
levels of SPRY1 transcripts in the stromal-vascular and
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the tumor compartments. Therefore, we performed
quantitative real time-PCR (qRT-PCR) and used
respectively mouse-specific and human-specific pri-
mers. As shown in Fig 2C, the designed primers are
species-specific, since false-template PCRs combining
human cDNA with mouse primers or mouse cDNA
with human primers failed to produce detectable
amounts of amplicons. In the stromal-vascular com-
partment, Spry1 expression was found to be higher in
mice treated with 16 K-Ad than in mice treated with
the control vector (Fig 2D). Similar results were
obtained for the other Sprouty family member Spry2
(see Additional file 1). No SPRY1 expression could be
detected in the human tumor compartment even after
40 cycles of PCR amplification (Fig 2E).
We also assessed the effect of 16 K hPRL on SPRY1
expression in HCT116 in vitro. Although we were
unable to detect SPRY1 in the tumor samples of the in
vivo experiment, the Ct values of SPRY1 in the HCT116
cells in vitro were very high but in detection rate. In
these tumor cells in culture, 16 K hPRL treatment had
no effect on the mRNA expression level of SPRY1
neither after 4 h or 24 h of treatment with 10 nM 16 K
hPRL (Fig 2F). These results suggest that 16 K hPRL
treatment specifically amplifies endothelial SPRY1
expression.
SPRY1 expression in endothelial cells is dependent of
NF-B activity
We have previously demonstrated a central role for
NF-B in the molecular response of 16 K hPRL in
endothelial cells [23]. To assess the importance of
NF-B in 16 K hPRL-induced SPRY1 expression, we
used the chemical inhibitor of NF-kB activation, BAY
1170-82, which interferes with IKK activation [26]. First,
we transfected ABAE cells with a pElam-Luc reporter
gene vector which allows specific detection of NF-B
activity. As expected, luciferase activity was increased 15
fold after 16 K hPRL treatment. This induction was
reduced in a dose-dependent manner by pre-incubation
of the cells with BAY 1170-82 (Fig 3A). In addition,
inhibition of NF-B activity by pre-incubating the cells
with BAY 1170-82 inhibited the induction of SPRY1 by
16 K hPRL (Fig 3B). Interestingly, treatment of ABAE
cells solely with BAY 1170-82 also significantly reduced
SPRY1 expression in ABAE cells. These results demon-
strate that the expression of SPRY1 in endothelial cells
is dependent of NF-kB activation.
SPRY1 silencing protects cells from apoptosis and induces
endothelial cell adhesion, migration, and tube formation
To investigate the specific function of SPRY1 in
endothelial cells, we used small interfering RNA. ABAE
cells transfected with 50 nM of SPRY1 siRNA duplexes
Figure 1 16 K hPRL treatment increases SPRY1 mRNA and
protein levels in primary and human endothelial cells. A. SPRY1
mRNA expression measured by qRT-PCR in RNA extracted from
ABAE cells incubated for 1 to 6 hours with 16 K hPRL (10 nM). Data
were normalized to the GAPDH transcript level. B. SPRY1 protein
expression analyzed by Western blotting on total protein extracted
from ABAE cells treated for 1 to 6 hours with 16 K hPRL (10 nM).
The level of beta-tubulin was measured as an internal control.
Bottom panel: quantification of the top panel. A densitometry
analysis was performed using ImageJ software and showed the
SPRY1/beta tubulin intensity. C. The subcellular localization of SPRY1
was determined in ABAE cells by immunofluorescence microscopy
using an antibody specific for SPRY1 (red) and a dapi staining for
nuclei (blue) A, B. Mean fold change versus untreated cells (/) is
reported with the corresponding SD (n = 3). *:significant at
p < 0.05. The results shown are representative of at least three
independent experiments.
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Figure 2 16 K hPRL increases endothelial SPRY1 expression in vivo in a mouse xenograft tumor model. Effect of 16 K hPRL on tumor
growth. Representative data of 2 independent experiments are shown. A. Western blotting performed on protein extracts from tumors (100 μg
protein) with an anti-hPRL polyclonal antibody, recombinant 16 K hPRL (100 ng, 16 K hPRL) was used as control. B. Tumor growth curves of
HCT116 tumor cells in mice treated with 16 K-Ad or Null-Ad. C. Agarose electrophoresis of products of end-point PCR performed with human-
specific (h) or mouse-specific (m) primers on cloned full-length mouse or human SPRY1 or PPIA (cyclophilin A) cDNA. D. Analysis of Spry1 mRNA
expression by qRT-PCR using mouse-specific primers in RNA extracted from tumors. Data were normalized with respect to the mouse ppia
transcript level. E. Agarose electrophoresis of products of end-point PCR performed with human-specific or mouse-specific primers on RNA
extracted from tumors harvested from nude mice injected with HCT116 tumor cells and treated with 16 K-Ad or control Null-Ad adenovirus.
F. The SPRY1 mRNA expression measured by qRT-PCR in RNA extracted from HCT116 cells after 2 or 4 h of treatment with 16 K hPRL (10 nM).
The data were normalized to the PPIA transcript level. D, F. Data are mean fold change + SD (n = 3), *: significant at p < 0.05. The results shown
are representative of at least three independent experiments.
Figure 3 SPRY1 expression in endothelial cells is dependent of NF-B activity. A. Luciferase activity of ABAE cells transfected with the
pElam-Luc reporter gene vector and cultured for 1 h with or without treatment with increasing concentrations of BAY 1170-82 prior to
incubated for 3 h without specific treatment (control) or with 16 K hPRL (10 nM). Luciferase activities were normalized to the b-galactosidase
activity. B. SPRY1 mRNA expression analyzed by qRT-PCR in RNA extracted from ABAE cells cultured with or without treatment with BAY 1170-82
(5 μM) prior to 2 h-incubation with 16 K hPRL (10 nM). Data were normalized to the GAPDH transcript level. Data are mean fold change + SD
(n = 3), *: significant at p < 0.05. The results shown are representative of at least three independent experiments.
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demonstrated a significant reduction of SPRY1 mRNA
levels 48 h post-transfection. We tested two different
SPRY1 siRNA duplexes which both lead to a 60%
decline of SPRY1 mRNA levels in endothelial cells com-
pared to a control-siRNA (Fig 4A). This was confirmed
at the protein level by Western blotting on cell extracts
obtained 48 h post-transfection (Fig 4B). The tested
siRNA constructs were specific for SPRY1 and did not
effect the expression of the other Sprouty family mem-
bers SPRY2 and SPRY4 (see Additional file 2 - SPRY2
and SPRY4 expression after SPRY1 silencing). Expression
of SPRY3 was not detected in ABAE cells. Both siRNA
duplexes directed against SPRY1 were used in the func-
tionality assays on primary endothelial cells 48 h post-
transfection.
Since SPRY1 expression is regulated by NF-B activa-
tion and NF-B is shown to be involved in endothelial
cell apoptosis by activation of caspase-3 [20], we first
investigated a possible role for SPRY1 in endothelial cells
in this process. Activation of the effector protease cas-
pase-3 is one of the most common events in the apopto-
tic signaling pathway. SPRY1 knockdown was found to
reduce caspase-3 activity in endothelial cells by 60% as
compared to the activity measured in cells transfected
with the control siRNA duplex (Fig 4C). Similar results
were obtained with both siRNA duplexes (data not
shown). Thus, we can conclude that a decreased expres-
sion of SPRY1 protects endothelial cells from apoptosis.
Next we tested the effect of decreased SPRY1 expres-
sion in several other angiogenesis related processes.
Interactions of endothelial cells with the extracellular
matrix (ECM) are crucial, as endothelial cells are ancho-
rage-dependent in numerous physiological processes.
We examined the adhesion of transfected endothelial
cells on 2 major ECM components vitronectin and
fibronectin. Forty-eight hours after transfection with a
SPRY1 siRNA duplex or with the non-silencing control
siRNA duplex, the level of adhesion on vitronectin or
fibronectin was slightly but significantly higher in cells
where SPRY1 was silenced (Fig 4D). These data suggest
that SPRY1 knockdown increases endothelial cell adhe-
sion to ECM proteins.
Once endothelial cells have adhered, cells degrade the
ECM which allows migration of the cells. We assessed
the effect of SPRY1 silencing in endothelial cells on cell
migration via a modified Boyden chamber with cells col-
lected 48 h post-transfection. bFGF was used as che-
moattractant for the endothelial cells. In this experiment
cells transfected with the SPRY1 siRNA duplex showed
a 70% greater migration capacity than control-duplex-
transfected cells in the absence of bFGF. When bFGF
was added to stimulate cell migration, an increased
migration of 60% was observed in SPRY1 siRNA trans-
fected cells compared to control cells (Fig 4E).
To further characterize the effect of SPRY1 on angio-
genesis, we performed a Matrigel tube formation assay
on SPRY1-siRNA-duplex- and control-siRNA-duplex-
transfected cells. When plated on Matrigel, endothelial
cells develop into a network of capillary-like vessels
and thus provide an in vitro model of capillary forma-
tion. When tested, both control and SPRY1-silenced
cells formed networks of tube-like vessels after seeding
them on Matrigel in serum containing medium. How-
ever, cells transfected with SPRY1 silencing siRNA
showed an increased network complexity as deter-
mined by the number of intersections (Fig 4F). All
together these results indicate that the presence of
SPRY1 expression in endothelial cells prevents
angiogenesis.
SPRY1 silencing increases MAPK activation and
endothelial cell proliferation by adapting cell-cycle
regulator expression
The last angiogenic process we investigated is one of the
most important ones namely endothelial cell prolifera-
tion. The inhibitory effect of SPRY1 on growth-factor-
induced MAPK activation has been widely demon-
strated. SPRY1 and SPRY2 are reported to inhibit bFGF-
induced tyrosine kinase receptor signal transduction by
inhibiting the pathway leading to activation of p42/44
MAPK [27]. We thus examined the effect of SPRY1
knockdown on p42/44 MAPK activity in endothelial
cells. ABAE cells were transfected with the SPRY1 or
control siRNA duplex, and were stimulated, after serum
starvation, with 10 ng/ml bFGF or 10% serum for
20 minutes. MAPK activation was monitored by immu-
noblotting with an antibody directed specifically against
the phosphorylated forms of p42/44 ERK. As expected,
we observed an increased level of phosphorylated p42/
44 ERK after bFGF or serum addition. In these condi-
tions, SPRY1-knockdown cells showed a significantly
higher level of p42/44 ERK phosphorylation than the
control cells. The overall level of p42/44 ERK appeared
unaffected, as determined by probing with an antibody
recognizing all forms of p42/44 ERK (Fig 5A).
Sustained activation of the ERK/MAPK signaling path-
way is crucial to allow cell cycle progression and is asso-
ciated with the induction of positive regulators of cell
proliferation and inactivation of cell cycle inhibitors
[28]. Having shown that SPRY1 decreases ERK/MAPK
activation, we examined if SPRY1 knockdown really sti-
mulates endothelial cell proliferation. Therefore, trans-
fected ABAE cells were serum starved and then treated
with bFGF or serum to induce cell proliferation. The
cells responded well to these proliferation stimuli by
showing a respectively two-fold and five-fold increase in
cell proliferation. Transfection of ABAE cells with
SPRY1 siRNA duplex increased proliferation of these
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Figure 4 SPRY1 silencing protects cells from apoptosis and induces endothelial cell adhesion, migration, and tube formation. A. SPRY1
mRNA levels quantified by qRT-PCR from ABAE cells transfected (48 h) with non-silencing siRNA (Control) or with two different SPRY1 siRNAs.
B. SPRY1 protein level measured by Western blotting from ABAE cells transfected as indicated in A. The beta-tubulin level was also measured as
an internal control. Bottom panel: quantification of the top panel: SPRY1/Beta tubulin. C. Apoptosis was assessed 48 hours after ABAE cell
transfection with non-silencing (Control) or with a SPRY1 siRNA by quantification of caspase-3 activity. D. Effect of SPRY1 silencing on adhesion of
ABAE cells to fibronectin or vitronectin. E. Migration in a modified Boyen chamber assay. 36 h after transfection cells were seeded in the upper
chamber of the Boyden. Migration was assessed by counting cells on the lower face of the membrane after 16 h. Arrow head: pore of the
membrane and arrow: cells stained with crystal violet. F. 36 h after transfection, ABAE cells were seeded on Matrigel and incubated for 16 h.
Living cells were labeled with calcein-AM. Quantitative analysis of network structures was performed by measuring the number of intersections
between tubes in the network (arrows). E, F: Top panel: representative images for migration and tube network formation assays. Bottom panel:
Quantification. A-F: Data are mean fold + SD (n = 3). The results are representative of at least three independent cell transfections. *: significant
at p < 0.05.
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cells even more as compared to cells transfected with
the control siRNA duplex (Fig 5B).
Cell proliferation is controlled by the activity of cyclin-
dependent kinases (CDKs), their essential coactivating
enzymes, cyclins and CDK inhibitors. Cyclin levels rise
and fall during the cell cycle, periodically activating
CDKs. Different cyclins are required at different phases
of the cell cycle. The three D-type cyclins (cyclins D1,
D2, and D3) act as essential sensors which respond to
mitogenic stimulation and, upon associating with CDKs,
allow cell entry into the G1 phase [29]. Among the dif-
ferent D-type cyclins, activation of the ERK/MAPK
pathway is known to allow transcription of the cyclinD1
gene [28]. Having shown that SPRY1 inhibition increases
cell proliferation and MAPK activation, we monitored
cyclinD1 expression in SPRY1-knockdown and control
endothelial cells. After serum starvation, transfected
ABAE cells were treated with serum for 24 h. Then,
RNA was extracted from the transfected cells and sub-
jected to qRT-PCR in order to measure the cyclinD1
transcript level. This level was found to be significantly
higher in the SPRY1-knockdown cells (Fig 5C).
Among the inhibitors of CDKs, the Cip/Kip-family pro-
teins p21, p27, and p57 can interact with a broad range of
cyclin-CDK complexes. These inhibitors inactivate CDK-
cyclin complexes and are essential to the cell cycle arrest
in a broad range of cell types [30]. Moreover, p21 has
been demonstrated to be regulated by the MAPK/ERK
signaling pathway [31]. This led us to study the effect of
SPRY1 knockdown on p21 expression in ABAE cells.
Expression of p21 was found to be decreased in SPRY1-
knockdown than in control cells when cells were cultured
in serum containing medium for 24 h after serum starva-
tion (Fig 5C). These results clearly show that SPRY1
negatively regulates endothelial cell proliferation, an
important process during new vessel formation.
Discussion
Since the emergence of angiogenesis as a crucial step in
tumor growth and metastasis, great efforts have been
Figure 5 SPRY1 silencing increases MAPK activation and endothelial cell proliferation by adapting cell-cycle regulator expression. ABAE
cells were transfected with non-silencing (Control) or SPRY1 siRNA for 48 h. A. Total protein was extracted from these cells and the level of
phospho-Erk1/2 protein was measured by Western blotting. The total level of Erk1/2 protein was used as an internal control. Bottom panel:
quantification of the top panel. A densitometry analysis was performed using ImageJ software showing phospho-Erk1/2/total Erk1/2 intensity.
B. Proliferation was assayed 48 hours after transfection by measuring BrdU incorporation. C. cyclinD1 and p21 mRNA expression quantified by
qRT-PCR from ABAE cells 48 h post-tranfection. Data were normalized to the level of GAPDH transcript. Mean fold change versus control is
shown with the SD (line above the bar, n = 3), *: significance at p < 0.05. The results shown are representative of at least three independent cell
transfections.
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made to discover new angiogenesis regulators. In order
to identify new genes that control angiogenesis, we pre-
viously performed a transcriptomic analysis on endothe-
lial cells after treatment with the potent angiogenesis
inhibitor 16 K hPRL [23]. In the list of 16 K hPRL upre-
gulated genes we found SPRY1, earlier described as a
regulator of branching during trachea development in
Drosophila [3]. As angiogenesis is morphologically
somewhat similar to branching of the Drosophila tra-
cheal system, SPRY1 appeared to be a good candidate.
In addition, SPRY1 is a strong inhibitor of growth-
factor-induced MAPK signaling required for angiogen-
esis [27,32] and SPRY1 was demonstrated to block
endothelial cell proliferation and differentiation by inhi-
bition of ERK/MAPK signaling induced by bFGF and
VEGF [24]. Moreover, SPRY2 and SPRY4, two other
SPRY-family members, are reported to play a role in
angiogenesis [8,9,33]. Based on these data, we hypothe-
sized that SPRY1 might be an endogenous angiogenesis
inhibitor and we therefore decided to study its proper-
ties in several angiogenesis models, including tumor-
induced angiogenesis in mice.
The results of the present study corroborate our
hypothesis. We first confirmed in vitro that treatment
with the angiostatic agent 16 K hPRL stimulates SPRY1
expression both on transcript- and protein-levels. We
further demonstrated in our xenograft tumor model that
16 K hPRL specifically enhanced the transcript-level of
SPRY1 in the (murine) vascular compartment. These
data might be very useful in future cancer treatment
since SPRY1 expression is repressed during tumor devel-
opment as shown in prostatic and breast cancers
[34,35]. Therefore, the re-expression of SPRY1 when
tumor growth is abolished might be a powerful tool to
monitor tumor response to angiostatic treatment or to
decide on treatment strategies.
We further show that SPRY1 silencing activates
endothelial cells to proliferate, adhere to ECM proteins
like fibronectin and vitronectin, to migrate, and to form
complex vascular networks in a capillary-like-tube for-
mation assay. In addition, SPRY1 silencing protects
endothelial cells from apoptosis. All these processes are
highly relevant to angiogenesis. At least some of the
observed effects of SPRY1 knockdown might be linked
to the previously described role of SPRY1 as an inhibitor
of the MAPK pathway [32,36]. Effectively, some reports
have already linked MAPK/ERK to cell migration. Pin-
tucci notably highlighted the necessity of ERK1/2 activa-
tion for bFGF-induced endothelial cell migration [37].
In line with these data, we observed an increased ERK1/
2 activation and a higher migration capacity in SPRY1-
silenced cells. Moreover, SPRY2, a family member of
SPRY1, has been shown to inhibit migration of tumor
cells in response to serum and several growth factors
[38]. They also demonstrated that the anti-migratory
effect of SPRY2 is mediated by the inhibition of Rac1
activation in epithelial cells [39]. According to our data,
SPRY1 seems to have similar effects to SPRY2 on
endothelial cell migration. However, further studies are
still needed to clarify whether Rac1 inhibition is also
involved in the anti-migratory action of SPRY1.
The adhesion of endothelial cells to the ECM plays a
major role in cell migration. To date, the potential invol-
vement of SPRY1 in endothelial cell adhesion to ECM
proteins has never been studied. According to our
results, deletion of SPRY1 potentiates adhesion of
endothelial cells to fibronectin and vitronectin. The dif-
ferential adhesion to vitronectin might be related to the
MAPK/ERK signaling as well. Previous reports have
shown in osteoblasts that inhibition of MAPK/ERK sig-
naling decreases adhesion of these cells on different sub-
strates, including vitronectin [40]. This was accompanied
by a reduction of avb3 integrin expression which was
shown to mediate adhesion to vitronectin. Adhesion to
fibronectin has also been shown to be dependent on
MAPK/ERK activation [41].
Proteins of the Sprouty family, like SPRY2, have been
demonstrated to possess anti-apoptotic properties.
Edwin and coworkers notably demonstrated that silen-
cing of SPRY2 abolishes the anti-apoptotic action of
serum in adrenal cortex adenocarcinoma cells [42].
Moreover, SPRY2 has also been implicated in the inhi-
bition of UV radiation-induced apoptosis in HRas-trans-
formed human fibroblasts [43]. Here, we reported a
pro-apoptotic effect for SPRY1, suggesting differential
roles for SPRY1 and SPRY2 in controlling apoptosis.
However, in a few cases, SPRY2 has been attributed to
pro- apoptotic capacities such as in differentiated neu-
ronal cells [44]. On the other hand, apoptosis can also
be regulated by the MAPK pathway, as demonstrated by
Gupta, who showed that VEGF protects HDMECs from
apoptosis by activating MAPK/ERK signaling [45]. The
pro-apoptotic role of SPRY1 deduced from our study
may thus be due to SPRY1-mediated inhibition of
MAPK signaling.
To understand how SPRY1 regulates cell proliferation,
we examined the MAPK related factors p21 and
cyclinD1, whose products respectively downregulate and
upregulate cell cycle progression [29,46]. The regulation
of p21 by the ERK signaling pathway however, has been
under debate. In some cases, ERK signaling induces p21
accumulation, as demonstrated in chondrocyte matura-
tion [47]. Other studies have highlighted the importance
of ERK1/2 inhibition in inducing p21 expression. For
example, Han and coworkers reported that fibronectin
induces lung cancer carcinoma cell proliferation by
activation of the MAPK pathway, leading to a reduction
in p21 expression [48]. Moreover, terbinafin-induced
Sabatel et al. Molecular Cancer 2010, 9:231
http://www.molecular-cancer.com/content/9/1/231
Page 8 of 13
cell-cycle arrest through an up-regulation of p21 in
HUVECs was shown to be mediated by the inhibition of
ERK activation [31]. We demonstrated here that the
induction of cell proliferation by SPRY1 silencing in
endothelial cells is associated with increased cyclinD1
and reduced p21 transcript levels. Therefore, our results
reinforce the inhibitory role of ERK1/2 in the regulation
of p21.
The results we obtained here are in line with the
effects we previously showed for the potent angiostatic
agent 16 K hPRL which was used to identify SPRY1.
Similar to SPRY1 which is upregulated by 16 K hPRL,
Tabruyn et al. demonstrated that 16 K hPRL induces
endothelial cell-cycle arrest in association with a
decrease in cyclinD1 expression and the induction of
p21 [21]. In addition we showed that SPRY1 expression
induced by 16 K hPRL requires NF-B activation like
the angiostatic protein 16 K hPRL. Therefore we
attempted to connect the effects of 16 K hPRL on
endothelial cells to SPRY1. However, 16 K hPRL still
induces apoptosis and inhibits proliferation after SPRY1
silencing (data not shown). Thus, SPRY1 does not seem
to be essential for the induced apoptosis or decreased
proliferation by 16 K hPRL. According to the microarray
data previously obtained [23], these results are not sur-
prising. The transcriptomic study revealed 216 tran-
scripts differentially expressed after 2 h of 16 K hPRL
treatment. So it could be predicted that suppression of
only one target gene of 16 K hPRL would not be able to
completely abolish the effects of 16 K hPRL. Neverthe-
less, the fact that endothelial cells respond opposite to
treatment with SPRY1 siRNA, regarding proliferation
and apoptosis, compared to 16 K hPRL treatment indi-
cates that SPRY1 might be involved in the effects of
16 K hPRL.
Conclusions
In summary, we have shown here that down-regulation of
endogenous SPRY1 increases angiogenesis-related pro-
cesses in endothelial cells. SPRY1 silencing notably
enhances endothelial cell proliferation, a finding possibly
linked to SPRY1-mediated modification of p21 and
cyclinD1 expression and/or inhibition of RTK-induced
MAPK activation. Involvement of SPRY1 in endothelial
cell adhesion to ECM proteins was demonstrated here for
the first time. In addition, we show in vivo an endothelial
cell specific increase of SPRY1 expression after treatment
with an angiostatic agent. This all strengthens our conclu-
sion that SPRY1 acts as an angiogenesis inhibitor and
makes it an interesting target for future cancer therapies.
Since, if SPRY1 silencing enhances tumor angiogenesis,
then restoring SPRY1 expression should be an interesting
way to reduce tumor growth.
Methods
Production of recombinant protein and chemical
compounds
Recombinant 16 K hPRL was produced and purified from
E. Coli as previously described [20]. The purity of the
recombinant protein exceeded 95% (as estimated by Coo-
massie blue staining) and the endotoxin level was found
to be 0.5 pg/ng recombinant proteins, as quantified with
the “Rapid Endo Test” from the European Endotoxin
Testing Service (Lonza, Verviers, Belgium). BAY 1170-82
was purchased from Calbiochem (La Jolla, CA).
Cell cultures
ABAE (Adult Bovine Aortic Endothelial) cells were iso-
lated as previously described [49]. The cells were grown
in low-glucose DMEM containing 10% fetal bovine
serum (FBS) and 100 U/ml penicillin/streptomycin.
Recombinant bFGF (Promega) was added (1 ng/ml) to
the culture every other day. Confluent cells correspond-
ing to passages 8 to 13 were used in the experiment.
HMVEC (Human Microvascular Endothelial cell) cul-
tures were maintained in EBM2 medium (Lonza, Walk-
ersville, Walkersville, USA) containing 0.1% hEGF,
0.04% hydrocortisone (kit EGM-2 SingleQuots, Cambrex
Bio Science Walkersville, Walkersville, USA), 10% FBS,
and 100 U/ml penicillin/streptomycin. HCT116 cells
(human colorectal carcinoma cells) were grown in
McCoy’s 5a medium containing 10% FBS and 100 U/ml
penicillin/streptomycin. HEK 293 (Human Embryonic
Kidney) cells and adenovirus-E1-transformed HEK 293
cells (BD Biosciences, San Diego, CA) were grown in
DMEM supplemented with 10% fetal calf serum (FCS),
1% non-essential amino acids, 100 U/ml penicillin/strep-
tomycin, and 2.5 μg/ml fugisone.
Adenovirus vectors
16 K-Ad is a defective recombinant E1-E3-deleted adeno-
virus vector encoding a secreted peptide consisting of the
first 139 amino acids of PRL. This adenovirus vector was
constructed as described in [16] with the help of the
Adeno-X expression system (BD Biosciences, Erembode-
gem, Belgium). Briefly, the 16 K hPRL complementary
DNA was cloned into a pShuttle vector in an expression
cassette, which was then inserted into the Adeno-X viral
DNA. Recombinant adenoviruses were constructed and
amplified in HEK 293 cells. The BD Adeno-X Virus Puri-
fication kit (BD Biosciences, Erembodegem, Belgium)
and the Adeno-X Rapid Titer Kit (BD Biosciences, Erem-
bodegem, Belgium) were used to perform purification
and titration, respectively, of the recombinant adeno-
viruses (according to the manufacturer’s instructions).
Null-Ad is a control adenovirus carrying an empty
expression cassette.
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Mice
Adult female NMRI nude mice (6-8 weeks of age) pur-
chased from Janvier Breeding (Elevage Janvier, France)
were used for tumor growth experiments. The animal
experiment protocol used was approved by the Institu-
tional Ethics Committee of the University of Liege.
Mouse xenograft tumor model
Subconfluent HCT116 cells were trypsinized, washed,
and resuspended in PBS. Cell suspension (3.106 cells in
50 μl PBS) was injected s.c. into the right flank of NMRI
nude mice 2 weeks before the first adenovirus adminis-
tration. Sixteen mice were used and randomly divided
into two groups of 8 mice. Mice received four intratu-
moral injections of 5.108 pfu 16 K-Ad or Null-Ad (con-
trol) starting when the HCT116 tumors reached 150
mm3. These injections were repeated every 2 days. Ten
days after the first adenoviral vector injection, the mice
were euthanized and their tumors harvested. Tumor
growth was assessed by measuring the length and width
of each tumor every 2 or 3 days and calculating tumor
volume by means of the formula: length × width2 × 0.5
[50].
SiRNA Transfections
Small interfering RNA (siRNA) duplexes were obtained
from Integrated DNA Technologies (Integrated DNA
Technologies, Coralville, USA), two targeting SPRY1 and
one negative control. Cells were transfected by the
CaPO4 method. Briefly, 90,000 ABAE cells were seeded
into a 6-well plate and allowed to adhere overnight. One
hour before transfection, the medium was replaced with
fresh medium without antibiotics. SiRNA-CaCl2 com-
plexes were made by first combining siRNA with 10 μl
of 2.5 M CaCl2. One hundred microliters of HSBP (280
mM NaCl, 1.9 mM Na2HPO4; 12 mM glucose, 10 mM
KCl; 50 mM Hepes, pH 7.05) were added and the mix
was incubated for one minute at room temperature.
Next the mix was added dropwise to the cells followed
by an incubation period of 16 h. Cells were then col-
lected and seeded for further tests.
Quantitative real time PCR (qRT-PCR) analysis
Total RNA was extracted with the RNeasy Mini Kit
(QIAGEN) according to the manufacturer’s instructions.
Synthesis of cDNA was performed from 1 μg total RNA,
which was reverse transcribed with the Transcriptor
First Strand cDNA Synthesis Kit (Roche, Clinical
Laboratories, Indianapolis, IN) according to the manu-
facturer’s instructions. The resulting cDNA was used for
quantitative real-time PCR with the one-step 2× Master-
mix (Diagenode, Liège, Belgium) containing SYBR
green. Thermal cycling was performed on an Applied
Biosystem 7000 detection system (Applied Biosystems,
Foster City, CA). No-template controls were run for all
reactions, and random RNA preparations were also sub-
jected to sham reverse transcription to check for the
absence of genomic DNA amplification. The relative
transcript level of each gene was obtained by the 2-ΔΔCt
method [51] and normalized with respect to the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (in vitro assays) or cyclophilin A (PPIA)
(mouse assays). Primers were designed with the Primer
Express software and selected so as to span exon-exon
junctions to avoid detection of genomic DNA (see Addi-
tional file 3 - List of primers used in quantitative RT-
PCR). In order to verify species specificity of the PCR,
PCR combining human or mouse cDNAs with human
or mouse primers have been performed on cloned
cDNAs for PPIA or Sprouty obtained form the German
Resource Center for Genome Research (RZPD, IMA-
GENES, Germany). For analysis by end-point PCR, the
final products of the qRT-PCR obtained after 40 cycles
of PCR was loaded on agarose gel for electrophoresis.
Preparation of cell extracts
Cells were washed twice with cold PBS and scraped into
lysis buffer [25 mM HEPES (pH 7.9), 150 mM NaCl,
0.5% Triton, 1 mM dithiothreitol, 1 mM phenylmethyl-
sulfonylfluoride] on ice. Insoluble cell debris was
removed by centrifugation at 10000 × g for 15 min. Ali-
quots of protein-containing supernatant were stored at
-80°C. Protein concentrations were determined by the
Bradford method, with the Bio-Rad protein assay
reagent (Bio-Rad Laboratories, Inc., Hercules, CA).
Western blot analysis
Soluble cell lysate (30 μg) was resolved by SDS-PAGE
(12%) and transferred to a polyvinylidene fluoride mem-
brane (Milipore Corp., Bedford, MA). Blots were
blocked overnight with 8% milk in Tris-buffered saline
with 0.1% Tween 20 and probed for 1 h (or 2 h at 37°C
for anti-SPRY1 antibody) with primary antibodies: anti-
Prolactin A602 (home-made), anti-SPRY1 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-phospho-
p44/42 Map Kinase (Thr202/Tyr204) antibody (Cell Sig-
naling Technology, Beverly, MA), anti-MAP Kinase 1/2
(Millipore, Billerica, MA), polyclonal rabbit anti-beta-
tubulin (Abcam plc, Cambridge CB4 OFW, UK). After
three washes with Tris-buffered saline containing 0.1%
Tween 20, antigen-antibody complexes were detected
with peroxidase-conjugated secondary antibody and an
enhanced fluoro-chemiluminescent system (ECL-plus;
Amersham Biosciences, Arlington Heights, IL).
Immunostaining
ABAE cells were fixed with paraformaldehyde 1% for 30
min and permeabilized with 0.2% Triton X-100 in PBS
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for 5 min. The samples were blocked with 0.2% bovine
serum albumin in PBS for 30 min and incubated with
rabbit anti-SPRY1 over night at 4°C. This was followed
by incubation with a goat anti-rabbit-Cy3 for 30 min.
Fluorescence was analyzed with an Olympus fluores-
cence microscope and a camera linked to the Analysis
software (Soft Imaging System GmbH, Münster,
Germany).
Caspase-3 activity assay
Control and SPRY1-siRNA-transfected cells were plated
in 24-well culture plates at a density of 20,000 cells per
well in 500 μl of 10% FCS/DMEM. Caspase-3 activity
was measured 48 h post-transfection with the CaspACE
Assay System Fluorimetric (Promega Corp., Madison,
WI) according to the manufacturer’s instructions.
Analysis of cell proliferation
Transfected cells were plated in 96-well culture plates at
a density of 5,000 cells per well in 10% FCS/DMEM and
allowed to adhere for 6 h. Following this, complete med-
ium was replaced with DMEM free for 24 h. The trans-
fected cells were then incubated in 10% FBS/DMEM or
DMEM containing 10 ng/ml bFGF and proliferation was
analyzed 24 h later by measuring BrdU incorporation by
means of the Cell Proliferation ELISA, BrdU (Colori-
metric) (Roche, Clinical Laboratories, Indianapolis, IN)
Capillary network formation on a Matrigel matrix
The ability of SPRY1-siRNA-transfected ABAE cells to
form capillary networks was evaluated in a Matrigel™an-
giogenesis assay. Briefly, 80,000 cells were plated in 24-
well plates coated beforehand with 300 μl Matrigel.
Control-siRNA- and SPRY1-siRNA-transfected cells
were seeded into 200 μl of DMEM or 10% FBS/DMEM
for 16 h. In order to visualize vessels under a fluores-
cence microscope, the cells were incubated with calcein-
AM (2 μM) for 20 min. Quantitative analysis of network
structures was performed by measuring the number of
connections between vessels in the network. Photo-
graphs were taken with an Olympus fluorescence micro-
scope and a camera linked to the Analysis software (Soft
Imaging System GmbH, Münster, Germany)
Migration assay
Eight-micrometer 24-well Boyden chambers (Transwell;
Costar Corp, Cambridge, MA) were used for cell migra-
tion assays. Both sides of the membrane were coated
overnight with 0.005% gelatin. The lower chamber was
filled with 600 μl DMEM containing 1% BSA and 10
ng/ml bFGF. ABAE cells transfected with siRNA
duplexes, as described above, were placed in 300 μl of
0.1% BSA/DMEM in the upper chamber and allowed to
migrate for 16 h at 37°C. After fixation, cells stained
with 4% Giemsa were counted on the lower side of the
membrane. Cell counting was performed with an ImageJ
http://rsbweb.nih.gov/ij/ macro relying on color thresh-
olding in the RGB color space, followed by connected
component labeling with the “Analyze Particles” func-
tion with size and circularity criteria. The same set of
parameters was used for the experiments, and detection
masks were produced and double-checked by visual
examination.
Adhesion assay
Cell adhesion experiments were performed in 96-well
plates coated with either vitronectin or fibronectin.
Wells were coated with 50 μl vitronectin (10 μg/ml) or
fibronectin (10 μg/ml) for 1 h, and then washed twice
with PBS. Briefly, 50,000 siRNA-transfected cells were
plated on the coated 96-well plates and allowed to
adhere for 1 h. The wells were then washed twice with
medium to remove non-adherent cells. The cells were
fixed and stained with 0.01% crystal violet in methanol,
then the wells were washed extensively with water and
the dye was solubilized in methanol. Quantification was
performed by reading the optical density at 550 nm with
a microplate reader (Wallac Victor2; Perkin Elmer,
Norwalk, Finland).
Luciferase reporter Assays
NF-B luciferase reporter assays were performed as pre-
viously described [20]. Luciferase activity was normal-
ized using the b-galactosidase activity with the b-gal
Reporter Gene Assay Kit (Roche).
Quantification and statistical analysis
Quantification of Western blots was performed using
ImageJ software http://rsbweb.nih.gov/ij/. All data are
expressed as means ± SD unless stated differently. Ana-
lyses for statistical significance (the Mann-Whitney test)
were carried out with Prism 4.0 software (GraphPad
Software, San Diego, CA, USA). Statistical significance
was set at P < 0.05.
Additional material
Additional file 1: SPRY2 expression in vivo in a mouse xenograft
tumor model after 16 K hPRL treatment. Analysis of SPRY2 mRNA
expression by qRT-PCR using mouse-specific primers in RNA extracted
from tumors. Data were normalized with respect to the mouse PPIA
transcript level. *: significant at p < 0.05.
Additional file 2: SPRY2 and SPRY4 expression after SPRY1 silencing.
ABAE cells were transfected with non-silencing siRNA (Control) or with
two different SPRY1 siRNAs. SPRY2 and SPRY4 mRNA levels were
measured by qRT-PCR 48 hours after transfection. Data were normalized
to the GAPDH transcript level. Mean fold change versus untreated cells is
shown with the SD (line above the bar, n = 3). *: significant at p < 0.05.
The results shown are representative of at least three distinct cell
transfections.
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Additional file 3: List of primers used in quantitative RT-PCR.
Sequences of all primers used in qRT-PCR experiments are listed.
Abbreviations
VEGF: vascular endothelial growth factor; RTK: receptor tyrosine kinase; ERK:
extracellular signal-regulated kinase; MAPK: mitogen-activated protein kinase;
SPRY: Sprouty; 16 K hPRL: 16 kDa N-terminal fragment of human prolactin;
bFGF: basic fibroblast growth factor; NF-B: nuclear factor B; ABAE: adult
bovine aortic endothelial; HMVEC: human microvascular endothelial cell;
siRNA: small interfering RNA; GAPDH: glyceraldehyde-3-phosphate
dehydrogenase; PPIA: peptidylprolyl isomerase A (cyclophilin A); CDK: cyclin-
dependent kinase; ECM: extracellular matrix.
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